CHMP recommends Eylea (Bayer HealthCare) for wet AMD

On 20 September 2012, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Eylea (aflibercept), 40 mg/ml, solution for injection intended for the treatment of Neovascular (wet) Age-related Macular Degeneration (AMD). The applicant for this medicinal product is Bayer Pharma AG. The active substance of Eylea is aflibercept, an antineovascularisation agent, (S01LA05) which acts by binding and inhibiting VEGF-A (Vascular endothelial growth factor-A). The product was approved for this indication by the FDA for Regeneron in November 2011.